Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > FROM DAY 1, I was right

<< Previous

Bullboard Posts

Next >>

Comment by Momo25on Dec 02, 2022 11:25am

126 Views

Post# 35146463

RE:FROM DAY 1, I was right

Same for me. Some fools diverted intentionally the attention of the shareholders by presenting the oncology program as much appealing as possible, while it was unknown to all of us . The only ones who know are TH board, and they know from the begining, and they know the phase 1a-b is not working but still hiding the truth until today.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism